Published in Science · View the paper (DOI)
Researchers at Adimab isolated a broad panel of neutralizing anti-Ebola virus antibodies from a survivor of the 2014 outbreak. The study highlights the speed and effectiveness of Adimab's single B cell isolation platform, which was able to identify over 300 monoclonal antibodies within weeks of receiving a blood sample.
Coverage from 3 institutions